Deadline: 28-May-25
The Pfizer Foundation and the American College of Cardiology are collaborating to offer a new grant opportunity seeking proposals for quality improvement initiatives that will increase identification and accurate diagnosis of heart failure patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
Grants will be awarded in support of organizations/institutions working to decrease delays in identification and diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) due to it being underrecognized in a significant proportion of patients with heart failure.
Areas of Interest
- Clinical Area: Care Management of transthyretin amyloid cardiomyopathy (ATTR-CM)
- Improve the capabilities for ATTR-CM identification and diagnosis among heart failure patients with a preferred focus on hospitalized heart failure patients
- Reduce the time to correct diagnosis, among a broad audience of healthcare professionals, including increasing coordination of care across specialties
- Define and implement interventions to improve the patient’s holistic management (e.g. identification of ATTR-CM on first heart failure (HF) admission, post HF hospitalization discharge management)
- Utilization of existing and sustainable AI & Digital Health tools to identify and diagnose ATTR patients at risk for heart failure
- Defining and augmenting quality and performance measures for the screening, diagnosis and/or post discharge management of heart failure patients with underlying ATTR-CM.
Funding Information
- Individual projects requesting $75,000-$100,000 will be considered. They anticipate funding 3 projects.
- Duration: Proposed QI projects should be conducted within a 12-month timeframe to allow for a meaningful data collection period. An additional 3 months for outcomes/evaluation can be included.
Eligibility Criteria
- The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional organizations; government agencies; and other entities with a mission related to healthcare improvement.
- Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).
- The applicant must be the Project Lead/Principal Investigator (PI) or an authorized designee of such individual (e.g., Project Lead/PI’s grant/research coordinator).
- The Project Lead/PI must be an employee of the requesting organization.
For more information, visit The Pfizer Foundation.
